-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Whether in the world or in China, lung cancer is the malignant tumor with the highest incidence and is the main cause of cancer death.
Whether in the world or in China, lung cancer is the malignant tumor with the highest incidence and is the main cause of cancer death.
According to the " Standards for Diagnosis and Treatment of Primary Lung Cancer (2018 Edition)", the five-year survival rate of NSCLC patients in China is only about 5% , and the current status of treatment needs to be improved.
At the North American Lung Cancer Conference last year, the long-term survival data of pembrolizumab (Keytruda, K drug) combined with chemotherapy (carboplatin + pemetrexed) in the first-line treatment of advanced NSCLC was announced: more than half of the patients survived for more than 3 years, compared with chemotherapy, death The risk is significantly reduced by 29%, which brings hope to the majority of NSCLC patients.
At the North American Lung Cancer Conference last year, the long-term survival data of pembrolizumab (Keytruda, K drug) combined with chemotherapy (carboplatin + pemetrexed) in the first-line treatment of advanced NSCLC was announced: more than half of the patients survived for more than 3 years, compared with chemotherapy, death The risk is significantly reduced by 29%, which brings hope to the majority of NSCLC patients.
Surgical resection is still the standard treatment for early NSCLC management .
Given that previous studies have used inaccurate definitions of cancer diagnosis dates, little is known about the relationship between delayed surgical treatment and oncology results in NSCLC patients.
Given that previous studies have used inaccurate definitions of cancer diagnosis dates, little is known about the relationship between delayed surgical treatment and oncology results in NSCLC patients.
This retrospective cohort study was conducted using a new data set from the Veterans Health Administration (VHA) system.
Quantify delayed surgical treatment by clinical or radiological methods
Quantify delayed surgical treatment by clinical or radiological methodsAmong the 9904 patients with clinical stage I NSCLC who underwent surgical treatment, 9539 (96.
Among the 9904 patients with clinical stage I NSCLC who underwent surgical treatment, 9539 (96.
In general, factors associated with an increased risk of recurrence include younger age (for every 1 year younger, the risk increases by 8%), a higher Charlson complication index score (for every 1 unit increase, the risk increases by 5.
The relationship between radiotherapy treatment time (RTTS) and the probability of recurrence
The relationship between radiotherapy treatment time (RTTS) and the probability of recurrenceAfter more than 12 weeks, the risk of recurrence increased by 0.
After more than 12 weeks, the risk of recurrence increases by 0.
In summary, this study found that surgery delayed for more than 12 weeks is associated with an increased risk of recurrence and a decreased survival rate.
references:
references:Heiden BT, Eaton DB, Engelhardt KE, et al.
Heiden BT, Eaton DB, Engelhardt KE, et al.
com/journals/jamanetworkopen/fullarticle/2780403" target="_blank" rel="noopener">Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non--Small Cell Lung Cancer.
JAMA Netw Open.
2021;4(5):e2111613.
doi:10.
1001/jamanetworkopen.
2021.
11613 com/journals/jamanetworkopen/fullarticle/2780403" target="_blank" rel="noopener">Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non--Small Cell Lung Cancer.
Leave a message here
